Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-N53 in Digital Ulcers in Systemic Sclerosis
NCT06954597Phase 2Recruiting
- Sponsor
- Topadur Pharma AG
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of TOP-N53 in Digital ulcer (5 arms), sponsored by Topadur Pharma AG. Primary endpoints: Local treatment emergent adverse events up to 37 days and Investigator-solicited digital ulcer-related patient reported outcome - Pain up to 37 days. Started Feb 2025; status: recruiting.
02
Drugs
TOP-N53
03
Conditions
Digital ulcer
Beyond the preview
Go deeper on NCT06954597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954597.